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The prion agent is the infectious particle causing spongiform encephalopathies in animals and humans and
is thought to consist of an altered conformation (PrPSc) of the normal and ubiquitous prion protein PrPC. The
interaction of the prion agent with the immune system, particularly the humoral immune response, has
remained unresolved. Here we investigated the immunogenicity of full-length native and infectious prions, as
well as the specific biological effects of the resulting monoclonal antibodies (MAbs) on the binding and
clearance of prions in cell culture and in in vivo therapy. Immunization of prion knockout (Prnp0/0) mice with
phosphotungstic acid-purified mouse prions resulted in PrP-specific monoclonal antibodies with binding
specificities selective for PrPSc or for both PrPC and PrPSc. PrPSc-specific MAb W261, of the IgG1 isotype,
reacted with prions from mice, sheep with scrapie, deer with chronic wasting disease (CWD), and humans with
sporadic and variant Creutzfeldt-Jakob disease (CJD) in assays including a capture enzyme-linked immu-
nosorbent assay (ELISA) system. This PrPSc-specific antibody was unable to clear prions from mouse neuro-
blastoma cells (ScN2a) permanently infected with scrapie, whereas the high-affinity MAb W226, recognizing
both isoforms, PrPSc and PrPC, did clear prions from ScN2a cells, as determined by a bioassay. However, an
attempt to treat intraperitoneally prion infected mice with full-length W226 or with a recombinant variable-
chain fragment (scFv) from W226 could only slightly delay the incubation time. We conclude that (i) native,
full-length PrPSc elicits a prion-specific antibody response in PrP knockout mice, (ii) a PrPSc-specific antibody
had no prion-clearing effect, and (iii) even a high-affinity MAb that clears prions in vitro (W226) may not
necessarily protect against prion infection, contrary to previous reports using different antibodies.
Prions (PrPSc), the abnormal conformational isoforms of the
cellular prion protein (PrPC), are responsible for invariably
fatal neurodegenerative diseases of humans and animals (1,
35). Because they are transmissible and thereby induce char-
acteristic morphological changes in the brains of affected indi-
viduals, these diseases have been termed transmissible spongi-
form encephalopathies (TSE). The current “protein-only”
hypothesis postulates conformational changes of PrPC result-
ing in the infectious, abnormal, -sheet-rich, insoluble, multi-
meric pathological isoform PrPSc in the absence of a specific
nucleic acid or any other known infectious particle (39). Re-
cent experiments with recombinant prion protein biochemi-
cally manipulated to result in the formation of infectious PrPSc
strongly support the “protein-only” hypothesis (10, 22, 23).
Even though the primary amino acid sequence is the same
for both the cellular and pathogenic PrP isoforms (5, 29), the
two isoforms of PrP show considerable differences in their
folding (31), leading to different biochemical properties that
can be used to distinguish PrPC from PrPSc (7, 24). In partic-
ular, the partial resistance of PrPSc to treatment with protei-
nase K (PK), which contrasts with the sensitivity of the cellular
form PrPC to this enzyme, has been used in the past to distin-
guish between these two isoforms (24). However, this indirect
detection method for PrPSc has many disadvantages, because,
for example, PK digestion of PK-sensitive prions may lead to
false-negative results (38).
The generation of antibodies specific for the pathological
isoform PrPSc was greatly accelerated by the availability of
prion protein knockout (Prnp0/0) mice (9, 36). So far, various
antigens had been used to generate monoclonal antibodies
(MAbs), including PrP-encoding DNA and RNA (20, 21), re-
combinant PrP (19, 34, 42), synthetic peptides (2, 15, 30, 45),
and scrapie-infected tissue culture cells (28). The first mono-
clonal antibody showing specificity for PrPSc, 15B3, had been
obtained after immunization of Prnp0/0 mice with recombinant
bovine PrP (19). Immunization of mice with a sequence com-
prising repetitions of the short peptide motif YYR yielded
MAbs exclusively precipitating PrPSc from sheep with scrapie
cases and from Creutzfeldt-Jakob disease (CJD) patients (32).
Finally, Moroncini and coworkers cloned recombinant anti-
bodies with specificity for PrPSc by grafting a prion protein
peptide into an IgG antibody against HIV-1 Env (25, 26, 40).
In spite of the publication of several PrPSc-specific mono-
clonal antibodies in recent years (19, 25, 26, 32, 40), the ther-
apeutic potential of such antibodies has not yet been reported.
Here we investigated the antibody immune response to so-
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dium phosphotungstic acid (NaPTA)-precipitated full-length
infectious PrPSc and evaluated the resulting antibodies by con-
formation specificity and their ability to cure prion infections in
vitro and in vivo.
MATERIALS AND METHODS
Mice. tga20 (13), Prnp0/0 (9), Tg33 (37), and BALB/c mice were bred at the
Friedrich-Loeffler-Institut (FLI), Tu¨bingen, Germany. Transgenic mice were a
kind gift from C. Weissmann and A. Aguzzi. Infected mice were monitored twice
a week initially and then daily after the development of clinical symptoms. Mice
were terminated in the end stage of disease. The number of mice and the
experimental design had been approved by local authorities (Regional Board;
permission numbers FLI 204/02 and FLI 216/04). All experiments were con-
ducted in compliance with German and European laws and guidelines for animal
protection.
TSE strains. An RML strain seed of the scrapie agent was kindly provided by
A. Aguzzi, Zu¨rich, Switzerland, and was propagated in CD1 mice. The 263K
hamster scrapie strain was a kind gift from M. Beekes, Berlin, Germany. The
sheep scrapie agent originated from diseased sheep, originally infected with brain
material from a natural case of scrapie, kindly provided by U. Agrimi and F.
Scholl, Italy. Samples from mock-infected white-tailed deer (infected with a
control brain homogenate) (samples 103 and 123) and samples from white-tailed
deer with chronic wasting disease (CWD) (samples 106, 112, and 121) were a
kind gift from E. Hoover, Colorado State University. Variant CJD (vCJD)
samples used for immune precipitations were provided by James Ironside,
Edinburgh, United Kingdom, and vCJD samples for the capture enzyme-linked
immunosorbent assay (ELISA) consisted of two reference probes from the
WHO (NHBY0/0003 and NHBY0/0014). Samples from cases of sporadic CJD
and genetic CJD were obtained from the German TSE Forum. Experiments with
scrapie strains and CWD strains were performed at the biosafety level 2 labo-
ratories of the FLI. Experiments using various CJD strains were conducted at the
Institute of Neuropathology of the University of Du¨sseldorf or at Prionics AG,
Schlieren, Switzerland, in authorized laboratories.
Cell lines. Bos2 cells (8) were a kind gift from A. Aguzzi, and ScN2a cells were
obtained from S. Prusiner, San Francisco, CA.
Immunization with native NaPTA-precipitated RML. For immunization, 250
l of a 10% brain homogenate of terminally scrapie infected CD1 mice, infected
with the RML strain, was precipitated with NaPTA as described previously (43).
The resulting pellet was dissolved in phosphate-buffered saline (PBS) and was
mixed with an adjuvant. The first and second immunizations were performed
intraperitoneally (i.p.) using the ABM-ZK adjuvant (Linaris, Germany), whereas
for booster immunizations, the ABM-N adjuvant (Linaris, Germany) was used.
Mice were immunized four times with NaPTA precipitates equivalent to 250 l
of 10% brain homogenate of terminally scrapie diseased CD1 mice. The last
booster injection was performed intravenously (i.v.) without adjuvant 4 days
prior to fusion. Mouse sera were monitored for PrP immunoreactivity by West-
ern blotting. Spleen cells were fused to P3X63Ag8.653 cells by using a modified
protocol of Ko¨hler and Milstein (17).
Cultivation of hybridomas. Hybridomas were grown in 96-well plates using
minimal essential medium (MEM) with nonessential amino acids (NEAA)
(Gibco, Invitrogen, Karlsruhe, Germany) and 10% fetal calf serum (FCS), and
antibody production was monitored by use of an immunoglobulin-detecting
ELISA.
Screening for PrP-specific antibodies. First, an ELISA using recombinant
mouse prion protein determined antibody specificity for PrP. All reacting hy-
bridoma supernatants were then verified by Western blotting on RML-infected
and control brain homogenates.
The epitopes of the MAbs generated were identified using a membrane-bound
peptide library (Pep-Scan; JPT Peptide Technologies, Berlin, Germany) consist-
ing of 13-amino-acid (aa) peptides spanning the prion protein from aa 23 to 230,
with an 11-aa overlap between neighboring peptides.
To identify PrPSc-specific MAbs, an ELISA using mouse brain homogenates of
scrapie-affected and control mice was employed. Ten percent homogenates of
scrapie brain or a control homogenate was generated in 0.32 M sucrose–0.5%
sodium deoxycholate–0.5% NP-40 using a ribolyzer (FastPrep FP120; Thermo
Savant/Bio101). Homogenates were precleared by centrifugation for 15 min at
15,300 rpm in a Sigma 2-16K centrifuge at 4°C. Supernatants were pooled and
stored at70°C until use. The pooled supernatant was diluted 1:100 in carbonate
buffer for the coating of ELISA plates (Multisorb; Nunc, Wiesbaden, Germany),
which was performed overnight at 4°C. After blocking at room temperature (RT)
with PBS containing 0.2% bovine serum albumin (BSA)–0.05% Tween 20 for
1 h, undiluted hybridoma supernatants were added for 1 h at RT. The ELISA
was developed using horseradish peroxidase (HRP)-conjugated goat anti-mouse
IgG (Dianova, Hamburg, Germany) in combination with 2,2-azinobis(3-ethyl-
benzthiazolinesulfonic acid) (ABTS; Roche, Mannheim, Germany), and absor-
bance was measured in a Sunrise ELISA reader (Tecan, Crailsheim, Germany).
Hybridoma supernatants showing a stronger reaction with the scrapie brain
homogenate than with the control brain homogenate were further tested by
immunoprecipitation.
Immunoprecipitation of prion protein. For immunoprecipitation, 1% brain
homogenate in Tris-buffered saline (TBS) with 0.3% sarcosyl was incubated with
a MAb overnight at 4°C. Precipitation was performed using formalin-fixed Staph-
ylococcus aureus for IgM or Pansorbin cells for IgG isotypes (Calbiochem,
Merck, Darmstadt, Germany). After a wash, precipitates were boiled and then
centrifuged for 1 min at 13,000 rpm, and the complete supernatant was used for
Western blotting.
SPR analysis. Binding kinetics was determined on a Biacore 1000 instrument
(Biacore AB, Uppsala, Sweden). Recombinant mouse PrP (1 M) was diluted in
10 mM sodium acetate (NaOAc) (pH 4.5) and was immobilized on a 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC)–N-hydroxysuccinimide (NHS)-ac-
tivated CM5 chip (Biacore) at 5 l/min. After immobilization and blocking with
ethanolamine, the chip was washed with 50 mM NaOH until a steady signal was
obtained. The final surface density was about 3,500 response units (RU). All
kinetic surface plasmon resonance (SPR) analyses were run at a 5-l/min PBS
flow, and the antibody was injected at different concentrations ranging from 10
to 200 nM. Association and dissociation were each recorded for 180 s. After each
cycle, the surface was regenerated with 50 mM NaOH. Kinetic data were calcu-
lated using BIAevaluation, version 4.1, software according to the bivalent analyte
model.
Immunohistological staining of PrP. Brains of infected and control mice were
fixed in 4% formalin and subsequently were treated with concentrated formic
acid for 1 h. After a wash with PBS, the brains were postfixed again using 4%
formalin. Sections (thickness, 4 m) were autoclaved in citrate buffer and were
treated with proteinase K for 3 min at 37°C using a Digest-All kit (Zymed). Slices
were stained using an HRP-conjugated secondary antibody (SuperPicture-HRP
Polymer Conjugate kit; Zymed, Invitrogen, Karlsruhe, Germany) for 10 min.
Signal amplification was performed using the Tyramide Signal Amplification
(TSA) kit (Perkin-Elmer, Rodgau, Germany), and the signal was developed
using diaminobenzidine (DAB substrate kit for peroxidase; Vector Laboratories,
Peterborough, United Kingdom). Brain slices were counterstained using hema-
toxylin.
Treatment of ScN2a cells. ScN2a cells were cultured in the presence of a
monoclonal antibody at various concentrations. At the indicated time points (see
Fig. 5), cells were again subcultured in the presence or absence of the antibody.
One subculture was treated with monoclonal antibody W226 for 31 days, and
then all cultures were continued in the absence of the antibody. For bioassays,
mice were injected intracerebrally (i.c.) with 2  104 cells per mouse. The
infectious titer of inoculated cells was calculated according to reference 16.
Cultures of ScN2a cells were treated in the presence of antibody W261 for as
long as 104 days. For cell blot analysis, all cells were seeded in parallel on glass
coverslips in 24-well plates and were cultured for a further two days. Cell blot
analysis for the detection of scrapie prion protein was performed as described
elsewhere (8).
ELISA with MAb W261 and 6H4-HRP. A 25-g/ml portion of MAb W261 was
diluted into PBS and applied to 96-well Nunc MaxiSorp plates for 2 h at room
temperature. After three washes with PBS-Tween (PBST), wells were blocked
with 0.1% BSA in TBS for 1 h. Ten percent brain homogenates in homogeni-
zation buffer (Prionics AG) were diluted 1:100, 1:500, and 1:1,000 in immuno-
precipitation buffer (Prionics AG) and were incubated for 2 h at room temper-
ature. After three washes with PBST, bound PrPSc was denatured for 15 min
using conditioning buffer (Prionics AG). Prion protein was detected using 10
ng/ml MAb 6H4 conjugated to HRP (Prionics AG) diluted in PBS containing
0.05% Tween 20 and 0.1% BSA. Unbound detection antibody was washed away
with PBST, and a luminescence signal was generated using the SuperSignal
ELISA Femto maximum-sensitivity substrate (Pierce). The readout was per-
formed using the MPL2 microplate luminometer (Berthold).
Production of antibody W226 and scFv W226 for therapy. Large amounts of
MAb W226 were generated by culture of hybridoma cells in cell spin bottles
using MEM-NEAA (Gibco, Invitrogen, Karlsruhe, Germany) with 10% ultralow
IgG FCS (PAN Biotech, Aidenbach, Germany) to prevent contamination with
bovine IgG molecules. Cultures were grown at 37°C under 5% CO2 until the
amount of hybridoma cells started to decrease. The culture medium was har-
vested, and cells and cell debris were separated from the antibody-containing
medium by centrifugation at 1,200 rpm in a Beckman TJ-6 centrifuge. Superna-
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tants were stored at 20°C until the antibody was purified by affinity chroma-
tography using protein A Sepharose (Amersham, Freiburg, Germany). scFv
W226 was expressed as described previously (27).
Statistical analysis. Survival times for different groups of mice in treatment
experiments were compared using GraphPad Prism, version 5, software. Groups
were compared by using the Mann-Whitney two-tailed t test.
RESULTS
Antigen preparation and screening of monoclonal antibod-
ies. As an immunogen, an enriched and highly purified prep-
aration of PrPSc obtained by NaPTA precipitation of mouse
scrapie strain RML (RML6) was obtained by a method de-
scribed by others (43). Since, to our knowledge, the infectivity
of NaPTA-precipitated pathological prion protein for mice
had not been reported previously, we first analyzed this bio-
logical property of the purified antigen by inoculating the pre-
cipitated antigen i.c. or i.v. into tga20 indicator mice. Infectivity
was demonstrated in both inoculation paradigms after 60 or
191 to 212 days, respectively, and prion disease was confirmed
by PK digestion and Western blotting (data not shown). These
results indicated that after the NaPTA precipitation, the dis-
ease-associated PrPSc conformation should be largely pre-
served.
For immunization, NaPTA-precipitated PrPSc in PBS was
mixed with an antibody multiplier adjuvant (ABM-ZK; Linaris,
Germany) without further treatment in order to preserve the
conformation. A serum antibody response in Prnp0/0 mice was
detected by Western blotting as early as 2 weeks after the first
immunization and increased in intensity after additional
booster injections (data not shown).
Five antibodies produced from hybridoma fusion recognized
the prion protein by Western blotting (W123, W187, W226,
W756, and W827). Species specificity experiments with West-
ern blotting revealed that most of the antibodies recognized
only the mouse and hamster prion proteins (W123, W226,
W756, and W827) (Table 1), whereas W187, recognizing the
octarepeat motif, also reacted with prion proteins from various
animal species and humans. In addition, clones from the same
fusion were screened by selective recognition of PrPSc versus
PrPC by immunoprecipitation of prion-infected mouse brain
homogenates versus normal mouse brain homogenates, re-
spectively. This screening revealed that antibodies W68 and
W261 are immunoreactive to PrP from scrapie-infected ho-
mogenates but not from normal brain homogenates (Fig. 1A),
and additional digestion of these precipitates with proteinase
K revealed the presence of proteinase K-resistant prion pro-
FIG. 1. Reaction patterns of PrPSc-specific MAbs in immunopre-
cipitation (IP). (A) MAbs W68 and W261 react exclusively with the
PrPSc isoform. (B and C) Treatment of precipitates with PK reveals the
presence of PK-resistant PrPSc in MAb-precipitated material for W261
(B) and W68 (C). (D) Treatment of samples with PK prior to immu-
noprecipitation with MAb W261 reveals the interaction of W261 with
the PK-resistant core of PrPSc. (E) (Right) Specific immunoprecipita-
tion of scrapie PrPSc from mouse (mo), hamster (ham), and sheep
(shp) samples with MAb W261. (Left) The presence of PrPC and PrPSc
is shown in parallel. (F) Specific immunoprecipitation from brain sam-
ples of deer with CWD. The presence of PrP is demonstrated by the
use of W226 (lower left). W261 reacts with CWD-affected brain sam-
ples but not with control brain samples, kindly provided by E. Hoover.
Immunoprecipitations were performed using 200 l of 1% brain ho-
mogenate, and complete supernatants of boiled precipitates were an-
alyzed by Western blotting. For input material, 30 l of 1% brain
homogenate was loaded per lane. Western blots using mouse tissue
were developed using antibody W226. Prion proteins on immune blots
with human tissue were detected using MAb 6H4 (19). For the detec-
tion of prion proteins of animal species other than mouse, antibody
POM-1 was used (34). The signal at 50 kDa corresponds to the heavy
chain of mouse immunoglobulin.
TABLE 1. Binding of monoclonal antibodies generated in this
study to PrP of different speciesa
Species
Bindingb of:
W123 W187 W226 W756 W827
Cats     
Cattle     
Deer    / 
Dogs     
Hamsters     
Llamas     
Humans     
Mice     
Mouflons  /   
Pigs  /   
Sheep     
a The specificity of the antibodies was determined using Western blotting.
b , no binding; /, background binding; /, weak binding; , strong
binding.
4540 PETSCH ET AL. J. VIROL.
tein (Fig. 1B and C). Furthermore, when PK-digested prion-
infected mouse brain was used for immune precipitation, MAb
W261 also proved specific for PrPSc, and its conformational
epitope was then inferred to be within the PK-resistant core
(Fig. 1D).
Biochemical characteristics and detection abilities of PrPSc-
specific MAbs. Since W68 and W261 essentially yielded the
same results, W261 was chosen for all further experiments
because of its preferable IgG isotype. MAb W261 was then
used for detecting reactivities against PrPSc from different an-
imal species. W261 pulled down PrPSc exclusively from brain
tissue homogenates of scrapie-diseased mice, hamsters, and
sheep, not from those of control animals (Fig. 1E).
Additional experiments examined the specificity of MAb
W261 for CWD of white-tailed deer. As shown in Fig. 1F, MAb
W261 specifically precipitated PrPSc from the brains of three
CWD-diseased white-tailed deer, but not from mock-infected
controls. In contrast, MAb W226, used as a control, was able to
detect both isoforms of the deer prion protein in uninfected
and infected brain samples.
For human prion diseases, MAb W261 specifically recog-
nized all pathological isoforms of CJD strains but did not react
with human control brains (Fig. 2A and B). The amount of
immunoprecipitated material from brain homogenates with
different CJD strains was variable but, with the exception of
genetic CJD, consistent with the different amounts of PrPSc
present in the homogenates used for immunoprecipitation, as
verified by proteinase K digestion and detection by antibody
6H4 (Fig. 2C).
In order to investigate the suitability of MAb W261 for
high-throughput serial testing without the need for centrifuga-
tion steps, we established a sandwich ELISA with MAb W261
as the capture antibody to retain the pathological prion protein
PrPSc. MAb W261-mediated binding of PrPSc was detected by
antibody 6H4-POD (19) in combination with chemilumines-
cence. Using this assay, only prion proteins from infected
sheep brains, not that of a control brain homogenate, were
detected (Fig. 3A). Similar discrimination could be observed
for human vCJD samples, confirming the specificity of MAb
W261 for sheep and human prions (Fig. 3B).
Conformation-insensitive specificity of MAb W226. Within
the same fusion, PrPSc-specific antibodies W68 and W261 were
identified, along with antibodies recognizing PrPC and PrPSc
equally well (W123, W187, W226, W756, and W827). For one
of the latter (W226), Biacore analysis demonstrated an excep-
tionally strong dissociation constant for recombinant mouse
FIG. 2. Immunoprecipitation of PrPSc from CJD samples with
MAb W261. (A) Detection of PrPSc in various sporadic (s) cases and
one genetic (g) case of CJD. (B) Detection of PrPSc in various CJD
cases, including vCJD. (C) Demonstration of various amounts of PrPSc
in spontaneous, genetic, and variant CJD cases tested in panels A and
B by Western blotting. Immunoprecipitations were performed using 1
ml of 1% brain homogenate, and complete supernatants of boiled
precipitates were analyzed by Western blotting. For input material, 30
l of 1% brain homogenate was loaded per lane. The signal at 50 kDa
corresponds to the heavy chain of mouse immunoglobulin.
FIG. 3. ELISA with MAb W261 as the capture antibody for the
detection of PrPSc. (A) Detection of sheep PrPSc; (B) detection of
vCJD PrPSc. The specificity of this capture ELISA is demonstrated for
sheep scrapie (A) and for vCJD (B). For each species, a control
homogenate from normal brains was only weakly recognized, whereas
the homogenate from scrapie- or vCJD-affected brains was clearly
detected in a dose-dependent manner. In conclusion, this sandwich
ELISA using MAb W261 is able to distinguish between TSE-infected
and uninfected tissue homogenates of sheep or humans without the
need for proteinase K digestion, demonstrating its usefulness for di-
agnostic assays. Negative controls (neg) are uninfected sheep or hu-
man brain homogenates. One microliter of 10% or further diluted
brain homogenate was used per sample in a volume of 200 l. The
results are given as relative light units (RLU). The proportions above
the graphs represent the values obtained divided by the value for the
negative control.
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prion protein, 523 1012 M (Fig. 4A). Relative conformation
insensitivity was determined by immunoprecipitation (data not
shown), immunohistochemistry under denaturing conditions
(Fig. 4B), and comparable detection of surface and intracellu-
lar PrP on both infected and uninfected mouse neuroblastoma
cells (Fig. 4C and D), showing that this antibody detected PrP
by all assays used, including denatured Western blotting, inde-
pendent of the PrP conformation.
Differential biological activity of PrPSc-specific and univer-
sal PrP antibodies in permanently scrapie infected cell lines.
The capacities of the MAbs resulting from immunizations with
purified infectious prions for shielding prions during cellular
replication were assessed in cell models of prion infection. We
tested whether the PrPSc-specific MAb W261 was also able to
reduce PrPSc levels in ScN2a cells. ScN2a cells were cultivated
in the presence of MAb W261 for more than 100 days and were
regularly tested for the presence of PrPSc by cell blot assays
(Fig. 5C). Culture of ScN2a cells in the presence of even large
amounts of MAb W261 (50 g/ml) did not reduce PrPSc con-
tents in these cells at any time point analyzed, demonstrating
the absence of therapeutic potential of the PrPSc-specific MAb
W261.
In contrast, as demonstrated by cell blot analysis, culture of
cells for 9 days or more in the presence of 10 g/ml MAb W226
resulted in a significant reduction in the level of PrPSc after
proteinase K treatment (Fig. 5A). In an experiment where
antibody treatment was discontinued after 31 days and cells
were passaged for 42 to 88 days, no PrPSc reappeared, proving
complete clearance of prions (Fig. 5B).
To confirm the efficiency of MAb W226 in curing cells from
PrPSc, antibody-treated cells were tested in bioassays by i.c.
inoculation into tga20 mice. Whereas mice inoculated with
untreated ScN2a control cells succumbed to scrapie after 84 
5 days, corresponding to 2.56 log LD50 (50% lethal dose),
those mice injected with cells treated for 12 days with MAb
W226 had to be sacrificed after 102  8 days, corresponding to
0.94 log LD50, and treatment for 31 days did not result in
disease and death, even after an observation period of 500
days (Fig. 5D). From these experiments we concluded that
MAb W226 is capable of curing scrapie-infected cells and
therefore might be a potential therapeutic antibody for curing
prion infection in vivo.
Treatment of scrapie-infected mice with monoclonal anti-
body W226 and scFvW226. In their landmark paper, White et
al. (44) demonstrated that an exogenously administered anti-
body was able to prevent an intraperitoneal prion infection,
suggesting that postexposure treatment of prion infection was
possible. We therefore tested the high-affinity MAb W226,
which binds to the same epitope as a MAb active against prions
from the study by White et al., in exactly the same experimen-
FIG. 4. Characteristic properties of MAb W226. (A) Biacore analysis of W226 reveals a dissociation constant of 523  1012 M. (B) Immu-
nohistochemical staining of mouse brain tissue. W226 stains PrPSc in tissues of RML-diseased mice. Magnifications, 10 (upper panels) and 40
(lower panels). (C) Detection of surface PrP in uninfected Bos2 (top) and ScN2a (bottom) cells by flow cytometry. (D) Detection of intracellular
PrP in permeabilized Bos2 (top) and ScN2a (bottom) cells. Flow cytometry was performed using a FACSCalibur flow cytometer (Becton Dickinson
[BD], Heidelberg, Germany) with secondary antibodies from BD and a Cytofix/Cytoperm kit (BD) for intracellular staining.
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tal setup. In addition, we cloned a recombinant variable-chain
fragment (scFv) from W226 into Escherichia coli and demon-
strated its in vitro antiprion activity by a bioassay (27).
C57BL/6 mice were infected intracerebrally and intraperito-
neally with a 105 or 103 dilution of a 20% brain homogenate
of the RML strain of the mouse-adapted scrapie agent. The
infectious titer of RML had been determined to be high
enough to lead to prion disease for all mice inoculated. Twen-
ty-eight days after infection, treatment of infected mice with a
monoclonal antibody or single-chain antibody fragment was
started, using 2 mg/mouse/day (W226) or 1 mg/mouse/day
(scW226) twice a week by intraperitoneal injection. Treatment
of mice infected via the i.c. route did not exhibit any prolon-
gation in the incubation period at all (data not shown), con-
sistent with previous data (44). Mice infected i.p. demonstrated
minimal prolongation of the incubation period when treated
for 10 weeks (Fig. 6A). Most of the mice treated for a much
longer period also exhibited minimal prolongation of the in-
cubation time, but one mouse in each group did not develop
symptoms of scrapie for 677 (scW226) or 694 (W226) days
postinfection (dpi), even when treatment was terminated at
320 dpi. Differences in mean incubation time between all
treated groups and the untreated group were statistically sig-
nificant (Fig. 6A) but did not result in the highly efficient
therapeutic impact, securing the survival of all peripherally
infected mice, that was described previously (44). Since differ-
ences between mice treated for 70 or 320 days were not sig-
nificant (P, 0.8413 for W226 and 1 for scW226), and since there
was no statistically significant difference between groups
treated with scW226 or W226 (P, 1 for 70 days and 0.8413 for
320 days of treatment), we conducted a second treatment ex-
periment using scW226 with a reduced incubation time. In the
second experiment, the impact of starting antibody treatment
of mice at 2 dpi was studied, and mice were treated with
FIG. 5. Cell blot immunoassays of scrapie-infected and antibody-
treated ScN2a cells tested for the presence of the pathological prion
protein PrPSc by PK digestion and immunostaining with MAb W226.
(A) Reduction of the PrPSc load in ScN2a cells after various days of
treatment (dot) with MAb W226. (B) Reduction and absence of PrPSc
in ScN2a cells after treatment with W226 for the indicated numbers of
days (0 to 31 days) (upper row) and following incubation for various
periods in the absence of the antibody (42 to 92 days) (lower row).
(C) Treatment of scrapie-infected ScN2a cells with the PrPSc-specific
MAb W261 did not alter the amount of PrPSc. ScN2a cells were
cultured with the indicated amounts of MAb W261 for 104 days and
were subsequently tested for the presence of the pathological prion
protein PrPSc. Analysis revealed no differences between proteinase
K-treated and untreated cells, indicating that cultivation with MAb
W261 had no influence on the PrPSc level in ScN2a cells. ctrl, control.
(D) Absence of disease transmission to tga20 mice from ScN2a cells
treated for 31 days with W226. Cell blotting was performed as de-
scribed previously (8). FIG. 6. Treatment of scrapie-infected mice with MAb W226 or
scW226 results in marginal prolongation of the incubation period after
peripheral prion inoculation. Mice were infected i.p. (A) Treatment
with W226 or scW226 was started at 28 dpi and continued for 10 or 46
weeks. Treatment of mice (n 	 5) resulted in only moderate but
statistically significant prolongation of the incubation period. The P
values for the differences between treated groups and the untreated
group are as follows: for mice treated with scW226 for 70 days, 0.0198;
for mice treated with W226 for 70 days, 0.0335; for mice treated with
scW226 for 320 days, 0.0048; and for mice treated with W226 for 320
days, 0.0088. (B) Treatment of mice from 2 dpi with scW226 for 66
days (n	 6) resulted in only a marginal increase in the incubation time
over that for untreated controls (n 	 8). The P value for the difference
between the untreated and scW226 groups is highly significant
(0.0035). Mice were treated with 2 mg/mouse (W226) or 1 mg/mouse
(scW226) twice a week. Symbols represent individual mice, and hori-
zontal lines indicate the median incubation times. C57BL/6 mice were
inoculated using dilutions of a 20% homogenate: 30 l of a 10e5
dilution for i.c. inoculation and 100 l of a 10e3 dilution for i.p.
inoculation. The endpoint titer of the scrapie pool used for the inoc-
ulation of mice was determined by i.c. inoculation of tga20 mice and
was calculated to be 10.6 log LD50 per g of brain according to the
method of Reed and Muench (37a).
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scW226 for 66 days. This treatment also resulted only in a
minimal, though highly significant (P, 0.0035), increase in the
incubation time and therefore confirmed the results of the
earlier trial (Fig. 6B).
The limited impact of treatment with MAb W226 or scW226
on the development of disease by peripherally infected mice, in
view of the strong effect in clearing prions from ScN2a cells
(Fig. 5), contrasts sharply with the great therapeutic benefit of
antibody therapy reported previously (44).
DISCUSSION
Our findings can be summarized in three major points, as
follows. (i) Full-length infectious prions are immunogenic in
PrP knockout mice and lead to an antibody response that
includes the generation of PrPSc-specific antibodies, as well as
universal PrP-recognizing antibodies. (ii) A highly PrPSc spe-
cific IgG1 subtype MAb, W261, was unable to cure ScN2a cells.
(iii) A high-affinity anti-PrP antibody, W226, or its recombi-
nant scFv was able to cure ScN2a cells but unable to protect
from an intraperitoneal prion infection when administered in
vivo.
The availability of PrPSc-specific antibodies for diagnostic
and therapeutic purposes has been a long-sought goal. Here
we could show that PrPSc conformation specificity is part of an
immune response elicited in prion-immunized mice, although
in this study, PrP knockout mice with an enlarged epitope
space for PrP were used. NaPTA-precipitated pathological
prion protein is highly polymeric, as demonstrated by electron
microscopy (38). It is therefore reasonable to argue that the
polymeric nature of the NaPTA-precipitated antigen is respon-
sible for the induction of a strong antibody response, as has
been exemplified by the work of Bachmann et al. with polymers
of the viral glycoprotein (GP) of vesicular stomatitis virus
(VSV), showing stronger B-cell responses to polymers than to
monomers of the GP (3). This stronger stimulation of the
immune response is thought to be induced by B-cell receptor
cross-linking through the highly ordered GP that is found on
the viral surface of VSV (4). Therefore, we assume that the
polymeric nature of the NaPTA-precipitated PrPSc is also able
to induce a strong B-cell response against PrPSc.
The potential usefulness of W261 for diagnostic purposes
was demonstrated by the establishment of an ELISA with
W261 as the capturing antibody (Fig. 3).
A recently published study demonstrated the detection of in-
fectious and noninfectious aggregates of the prion protein by
PrPsc-specific monoclonal antibodies, suggesting that these MAbs
recognize structural elements common to infectious and nonin-
fectious aggregates of the prion protein (6). Since in our study the
interactions of the PrPsc-specific antibodies generated with non-
infectious prion protein aggregates were not analyzed, we cannot
exclude the possibility that these antibodies might also bind to
noninfectious aggregates of the prion protein in addition to bind-
ing to PK-resistant, supposedly infectious prions (Fig. 1B).
The intuitive concept of shielding the causative agent of a
disease by highly specific immune binding, e.g., neutralization of
a virus by antibodies, has long been held up for prion diseases.
However, early studies argued that antibodies binding to PrPC in
addition to PrPSc had improved prion clearance in permanently
scrapie infected cells (5a). Here we demonstrate the complete
lack of PrP conversion inhibition by PrPSc-specific MAb W261 in
vitro, even if treatment of cells was continued for more than 3
months, whereas under the same conditions, the universal MAb
W226, lacking conformation specificity, was effective (Fig. 5; see
also below). The reasons for the absence of antiprion activity for
MAb W261 may include the localization of PrPSc in cellular
compartments that are not accessible to PrPsc-specific antibodies.
If so, there would be no interference with the templating function
of PrPSc in the process of prion replication and/or prion storage,
and thus, PrPsc with a long half-life would be present. It is not
certain whether a generalization that all PrPSc-specific MAbs lack
antiprion activity can therefore be inferred, but the fact that no
such effect has been published so far could point to this possibility.
Interestingly, the only published PrPsc-specific peptide li-
gand showing antiprion activity in cell culture is a retroinverso
D-peptide of the complementarity-determining region (CDR)
of the MAb W226 heavy chain that, in contrast to full-length
W226, proved PrPSc specific, although the D-peptide has to be
used at relatively high concentrations (27).
In contrast to W261, the universal MAb W226, recognizing
both PrPC and PrPSc, cleared prions from ScN2a cells, as
FIG. 7. Sequence alignment of the variable heavy (VH) and light (VL) chains of W226 and ICSM18 by MUSCLE (Multiple Sequence
Comparison by Log Expectation) (11). The CDRs are boxed. BLAST analysis revealed 59% homology between W226 and ICSM18.
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validated by a bioassay (Fig. 5D). This effect has also been
shown by many other universal anti-PrP MAbs targeting helix
1 of PrP (12, 33). MAb W226 was therefore chosen for a
therapeutic trial against prion infection. So far, the successful
trial of White et al. with antibodies ICSM18 and ICSM35
leading to complete protection from peripheral prion infection
stands alone as the only published report of successful admin-
istration of antibodies against prion disease. Here we precisely
copied the treatment protocol of White et al. except that the
mouse strain inoculated was C57BL/6 rather than FVB and the
antibody was different (Fig. 7), although it binds to a similar
region in PrP (Table 2) (44). In a separate therapeutic ap-
proach, we also included recombinant scFv W226, which had
equally been proven by Mu¨ller-Schiffmann et al. to clear prions
in vitro (27), in order to provide a smaller ligand with poten-
tially easier passage through the blood-brain barrier.
Starting antibody administration either 28 days or 2 days
after i.p. inoculation did not lead to protection against prion
disease to the degree published by White et al., although a
single mouse in each of two long-term treatment groups sur-
vived for more than 600 days (Fig. 6A). Of note, the avidity of
bivalent W226 compared to that of monovalent scW226 did
not seem to play a major role with regard to the antiprion
effects. From these experiments, and considering the similarity
of experimental protocols, we draw the important conclusion
that the therapeutic success of antibodies against peripheral
prion infection must be influenced either by the strain of
mouse inoculated, the specific pharmacodynamic or pharma-
cokinetic characteristics of the antibody itself, or perhaps both.
A sequence comparison between the antibodies reveals signif-
icant differences between W226 and ICSM18, especially in the
hypervariable CDR regions (Fig. 7). These sequence differ-
ences could account for differences in the half-life and distri-
bution of the antibody in vivo; different affinities or other
binding characteristics could equally make a decisive differ-
ence. In summary, the ability of an antibody to cure ScN2a
cells, even if confirmed by a bioassay, does not predict success-
ful application in a therapeutic trial. A similar finding was
recently reported for quinacrine, a small molecule with clear
antiprion activity in ScN2a cells (18), which also failed in a
therapeutic trial (14). This failure, despite the fact that phar-
macokinetic obstacles such as the multidrug resistance com-
plex were circumvented successfully, was attributed to an evo-
lution of quinacrine-resistant prions (14). It remains to be
shown whether such an explanation could also account for the
inefficiency of W226 versus ICSM18 or if different factors ac-
count for the divergent results between these antibodies.
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